The following is a summary of the Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript:
Financial Performance:
Dare reported Q1 2024 general and administrative expenses of approximately $2.7 million.
R&D expenses were approximately $3.3 million—a 34% decrease compared to Q1 2023.
The Company's loss for the quarter was approximately $6.8 million.Dare ended the quarter with $3.6 million in cash and equivalents.
Dare secured a non-dilutive strategic royalty financing of $22 million and received total grant funding of approximately $1.8 million.
Business Progress:
Dare's product, XACIATO, is now available via prescription nationwide for treating bacterial vaginosis.
The Company is preparing for Phase 3 clinical trials of Sildenafil Cream 3.6% and Ovaprene.
They completed an end-of-Phase 2 meeting with the FDA regarding Sildenafil Cream.
Technological proof-of-concept for DARE-LARC1, Dare's pre-clinical candidate, was announced.
The company continues collaborations with major corporations including Organon for XACIATO and Bayer for Ovaprene.
Dare is planning to initiate a Sildenafil Phase 3 trial in early 2024, hopeful of it being the first Phase 3 study for female sexual arousal disorder.
The company is also progressing with DARE-LARC, a technology similar to 'Nexplanon', and is developing therapies for menopausal vasomotor symptoms and sexual pain.
Dare aims to position women's health at the forefront of innovation.
More details: Dare Bioscience IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
